About Us

Eurofins Discovery has supported drug discovery research for over 40 years. We are recognized as an industry leader for providing drug discovery researchers with the largest and most diverse portfolio of standard and custom in vitro safety and pharmacology assays and panels for drug screening and profiling.

In addition to our in vitro safety pharmacology strengths, we also offer a broad portfolio of over 3,500 drug discovery services and 1,800 products. These include medicinal and synthetic chemistry, in vitro pharmacology, safety pharmacology and efficacy, ADME-Tox, cell-based phenotypic assays, and custom proteins and assay development capabilities. We support a variety of drug discovery targets such as GPCRs, kinases, ion channels, nuclear hormone receptors and other proteins and enzymes.

Our teams across the world have broad drug discovery capabilities and proven experience in meeting a wide variety of project objectives successfully, delivering quality data and on-time performance. We have robust, efficient processes and quality systems in place to handle diverse types and volumes of samples and on-time delivery of reports.

Our broad global service capabilities and decades of experience in providing drug discovery services result in the delivery of high quality, reproducible study performance with few repeats and high client satisfaction. Eurofins Discovery's capabilities, expertise, knowledge and skill sets enable us to provide our clients with the benefit of being able to work with a single outsourcing provider (CRO) for their drug discovery programmes.

Our History

The Eurofins Discovery team was built by bringing together the market-leading discovery expertise of Panlabs (acquired in 2012 from Ricerca), Cerep (acquired in 2013), EMD Millipore's Discovery & Development Solutions business (acquired from Merck KGaA in 2014), Villapharma Research (acquired in 2017), DiscoverX (acquired in 2017), Selcia Drug Discovery (acquired in 2018), Beacon Discovery (acquired in 2021), DiscoveryBioMed (acquired in 2022) and Calixar (acquired in 2023). Eurofins Discovery comprises over 1,000 colleagues in seven sites across the world: St. Charles, MO (USA), Fremont, CA (USA), San Diego, CA (USA), Essex (UK), Celle Lévescault (France), Taipei (Taiwan), and Murcia (Spain). Our global team offers the high quality, reliable solutions and support our clients depend on to advance their drug discovery programmes.

Combining the broad, high quality, industry leading drug discovery products and services portfolios of our global teams enables us to support clients across the world with one of the industry’s largest and broadest portfolios.